中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

30 records (took 0.023 seconds)

    Pharmaceutical dosage forms comprising descarboethoxyloratadine
    21.
    发明申请
    Pharmaceutical dosage forms comprising descarboethoxyloratadine 审中-公开
    包含去甲氧基乙酰基吗啡的药物剂型

    公开(公告)号：US20030109540A1

    公开(公告)日：2003-06-12

    申请号：US10269871

    申请日：2002-10-15

    Applicant: Sepracor Inc.

    Inventor： Dean A. Handley ,  Paul D. Rubin

    IPC: A61K031/473

    CPC classification number: A61K45/06 ,  A61K31/445 ,  A61K31/4545 ,  Y10S514/826 ,  Y10S514/864

    Abstract: Methods utilizing descarboethoxyloratadine (nullDCLnull) for the treatment of allergic disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. Also included are methods for the treatment of allergic asthma using DCL and either a decongestant or a leukotriene inhibitor, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. The invention also encompasses the administration of DCL in a nasal or oral spray.

    Abstract translation: 利用去甲氧基吡咯烷（“DCL”）治疗过敏性疾病的方法，同时避免与其他非镇静抗组胺药相关的副作用的伴随责任。 还包括使用DCL和减充血剂或白三烯抑制剂治疗过敏性哮喘的方法，同时避免与其它非镇静性抗组胺药相关的副作用的伴随的责任。 本发明还包括以鼻腔或口腔喷雾剂施用DCL。

    S(-)rabeprazole compositions and methods
    23.
    发明申请
    S(-)rabeprazole compositions and methods 审中-公开
    S（ - ）雷贝拉唑组合物和方法

    公开(公告)号：US20030069280A1

    公开(公告)日：2003-04-10

    申请号：US10263558

    申请日：2002-10-02

    Applicant: SEPRACOR INC.

    Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

    IPC: A61K031/4439

    CPC classification number: A61K31/4439 ,  A61K31/00

    Abstract: Methods and compositions are disclosed utilizing optically pure S(null)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(null) isomer is also useful for the treatment of gastroesophageal reflux. S(null)rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 公开了使用光学纯的S（ - ）雷贝拉唑治疗人体溃疡的方法和组合物，同时显着减少与雷贝拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的S（ - ）异构体也可用于治疗胃食管反流。 S（ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

    Compositions and methods employing R (-) fluoxetine and other active ingredients
    25.
    发明申请
    Compositions and methods employing R (-) fluoxetine and other active ingredients 审中-公开
    使用R（ - ）氟西汀和其他活性成分的组合物和方法

    公开(公告)号：US20020151543A1

    公开(公告)日：2002-10-17

    申请号：US10158886

    申请日：2002-06-03

    Applicant: Sepracor Inc.

    Inventor： Timothy J. Barberich ,  Paul D. Rubin ,  Dean A. Handley

    IPC: A61K031/5513 ,  A61K031/137

    CPC classification number: A61K31/495 ,  A61K31/445 ,  A61K31/505 ,  A61K31/55 ,  A61K2300/00

    Abstract: Pharmaceutical compositions which comprises R(null) fluoxetine and one or more other biologically active compounds are disclosed. Methods of treating or preventing a disease or disorder, especially a psychotic or psychiatric disease or disorder, using the above pharmaceutical composition or by administering a R(null) fluoxetine in combination with one or more other biologically active compounds are also disclosed. Methods of treating patients having or at risk of having AIDS or HIV infection, cancer, cardiac disorder, post-myocardial depression and posttraumatic stress disorder using optically pure R(null) fluoxetine in combination with one or more other biologically active compounds are further disclosed.

    Abstract translation: 公开了包含R（ - ）氟西汀和一种或多种其它生物活性化合物的药物组合物。 还公开了使用上述药物组合物或通过与一种或多种其它生物活性化合物组合施用R（ - ）氟西汀来治疗或预防疾病或障碍，特别是精神病或精神疾病或病症的方法。 进一步公开了使用光学纯的R（ - ）氟西汀与一种或多种其它生物活性化合物组合治疗患有AIDS或HIV感染或有风险患有癌症，心脏病，心肌后抑郁症和创伤后应激障碍的患者的方法。

    Methods for treating apnea and apnea disorders using optically pure (+) norcisapride
    26.
    发明申请
    Methods for treating apnea and apnea disorders using optically pure (+) norcisapride 失效
    使用光学纯（+）诺西沙必利治疗呼吸暂停和呼吸暂停障碍的方法

    公开(公告)号：US20020147220A1

    公开(公告)日：2002-10-10

    申请号：US10075617

    申请日：2002-02-15

    Applicant: Sepracor Inc.

    Inventor： Paul D. Rubin ,  Timothy J. Barberich

    IPC: A61K031/445

    CPC classification number: A61K31/445 ,  A61K31/4468

    Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (null) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (null) stereoisomer.

    Abstract translation: 使用（+）诺西沙必利或其药学上可接受的盐的预防，治疗或治疗呼吸暂停，呼吸暂停障碍，贪食症，肠易激综合征，尿失禁，心动过缓，缓慢性心律失常，晕厥，其他障碍或其症状的方法， 基本上不含（ - ）立体异构体。

    R-lansoprazole compositions and methods
    29.
    发明申请
    R-lansoprazole compositions and methods 审中-公开
    R-兰索拉唑组合物和方法

    公开(公告)号：US20020042433A1

    公开(公告)日：2002-04-11

    申请号：US09981108

    申请日：2001-10-17

    Applicant: SEPRACOR INC.

    Inventor： William E. Yelle ,  Timothy J. Barberich ,  Paul D. Rubin

    IPC: A61K031/4439

    CPC classification number: A61K31/4439

    Abstract: Methods and compositions are disclosed utilizing optically pure (null) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (null) isomer is also useful for the treatment of gastroesophageal reflux. (null) Lansoprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 公开了使用光学纯的（+）兰索拉唑治疗人类溃疡的方法和组合物，同时显着减少与兰索拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的（+）异构体也可用于治疗胃食管反流。 （+）兰索拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

    Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion
    30.
    发明申请
    Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion 失效
    使用光学纯（+） - 安非他酮有助于戒烟和治疗疼痛和其他疾病的方法和组合物

    公开(公告)号：US20010011103A1

    公开(公告)日：2001-08-02

    申请号：US09803956

    申请日：2001-03-13

    Applicant: Sepracor Inc.

    Inventor： John R. McCullough ,  Paul D. Rubin

    IPC: A61K031/135

    CPC classification number: A61K31/137 ,  A61K9/2018 ,  A61K9/2059 ,  A61K31/135

    Abstract: Methods and compositions are disclosed utilizing the optically pure (null)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

    Abstract translation: 公开利用安非他酮的光学纯的（+）异构体来帮助戒烟，治疗吸烟和尼古丁成瘾以及治疗疼痛的方法和组合物，包括但不限于慢性疼痛，神经性疼痛和反射性交感神经营养不良 ，以及其他疾病如发作性睡病，慢性疲劳综合征，纤维肌痛，季节性情感障碍和经前期综合征，同时避免与外消旋安非他酮相关的不良影响。

Patent Agency Ranking